Non-Opioid Anesthesia for Perioperative Pain Management: Evidence, Implementation, and Future Directions — A Narrative Review

Non-Opioid Anesthesia for Perioperative Pain Management: Evidence, Implementation, and Future Directions — A Narrative Review Collin B. George, BS University of Washington Medical Center, Seattle, WA, USA Former Research Associate, Pacific Northwest National Laboratory (PNNL), Richland, WA, USA [email protected] ORCID: 0009-0007-8162-6839 This independent narrative review was conducted as part of premedical research and does not represent the views of UW Medicine. NOA for Perioperative Pain Management Abstract Background: The United States opioid epidemic, with approximately 81,000 opioidrelated overdose deaths in 2023, necessitates safer perioperative pain management strategies. Non-opioid anesthesia (NOA) employs multimodal approaches to minimize opioid exposure while maintaining effective analgesia. Objective: To synthesize recent evidence (2020–2024) on NOA’s efficacy, safety profile, and integration with Enhanced Recovery After Surgery (ERAS) protocols, prioritizing orthopedic and abdominal surgeries where evidence is strongest. Methods: This narrative review followed SANRA (Scale for the Assessment of Narrative Review Articles) principles, conducting comprehensive searches of PubMed, Scopus, and Cochrane Library through September 2024, including recently published 2024 studies and select articles in press for currency. Studies were selected based on relevance to NOA strategies including regional anesthesia, dexmedetomidine, ketamine, and ERAS protocols. Quality was assessed narratively using established frameworks. Results: NOA reduced perioperative opioid consumption by 50–80% across surgical specialties, with strongest evidence in orthopedic (65–75%) and abdominal (60–75%) procedures. Trade-offs included modestly higher postoperative pain scores in some studies (mean difference 0.39 on 0–10 scale, 95% CI 0.19–0.59). Regional anesthesia combined with multimodal agents shortened hospital length of stay by 1–2 days and reduced postoperative nausea and vomiting by up to 55% (RR 0.45). Adjunctive agents including dexmedetomidine and ketamine optimized analgesia but increased risks of bradycardia (5–15%) and hypotension (10–20%). Evidence for reduced opioid use disorder relapse remains preliminary (10–18% reduction, short-term follow-up only). Conclusions: NOA demonstrates substantial opioid-sparing effects with acceptable trade-offs in selected surgical populations. Wider adoption requires protocol standardization, enhanced clinician training, and long-term safety monitoring. Future research should prioritize adequately powered trials with extended follow-up to establish NOA’s role in addressing the opioid crisis. Keywords: non-opioid anesthesia; opioid-free anesthesia; multimodal analgesia; perioperative pain; ERAS; dexmedetomidine; ketamine; opioid crisis Word Count: Approximately 4,100 words (main text and abstract) Funding: None Conflicts of Interest: None declared 2 NOA for Perioperative Pain Management Summary Box What is Already Known •The United States opioid epidemic (approximately 81,000 overdose deaths in 2023) necessitates safer perioperative pain management strategies •Multimodal non-opioid anesthesia approaches show promise for reducing opioid exposure, but evidence remains fragmented across surgical specialties •Long-term outcomes including chronic pain development and opioid use disorder prevention remain poorly characterized •Implementation barriers including protocol heterogeneity, training requirements, and resource constraints limit widespread adoption What This Study Adds •Non-opioid anesthesia achieves substantial perioperative opioid reduction (50–80% across surgical specialties), with strongest evidence in orthopedic (65–75%) and abdominal (60–75%) procedures •Integration with Enhanced Recovery After Surgery (ERAS) protocols produces synergistic benefits: shortened hospital length of stay (1–2 days, 95% CI: −2.0to−1.5 days) and reduced postoperative nausea/vomiting (25–35%) •Trade-offs include modestly higher postoperative pain scores in some studies (mean difference 0.39 on 0–10 scale, 95% CI 0.19–0.59) and hemodynamic effects requiring monitoring (bradycardia 5–15%, hypotension 10–20%) •Evidence for opioid use disorder prevention benefits remains preliminary (10–18% reduced relapse rates) and limited by short follow-up periods (6–12 months), requiring validation through adequately powered trials with extended (≥24 month) follow-up •Substantial protocol heterogeneity (ketamine dosing 0.25–1 mg kg−1, dexmedetomidine infusion rates 0.2–0.7 µg kg−1h−1, varied regional techniques) and high statistical heterogeneity (I2>75%) in meta-analyses constrain reproducibility and definitive conclusions 3 NOA for Perioperative Pain Management •Critical research priorities include protocol standardization through multi-society consensus guidelines, adequately powered long-term outcome trials, dedicated studies in pediatric and geriatric populations, and comprehensive cost-effectiveness analyses •By eliminating perioperative opioid exposure, NOA provides a mechanistic pathway for primary prevention of new opioid use disorder cases — a public-health benefit that extends far beyond acute pain control. 4 NOA for Perioperative Pain Management 1 Introduction 1.1 The Opioid Crisis and Perioperative Pain Management The United States faces an ongoing opioid epidemic of staggering proportions. According to the Centers for Disease Control and Prevention (CDC), provisional data indicate approximately 81,083 opioid-related overdose deaths occurred in 2023, representing persistent severity despite intervention efforts [1]. Surgical opioid prescribing represents a critical entry point into the opioid crisis. Post-surgical patients routinely receive opioid prescriptions that far exceed actual consumption needs. Studies demonstrate that 67–92% of prescribed opioid pills remain unused after common surgical procedures, with a median of 2–3 weeks’ supply dispensed for procedures requiring only 3–5 days of opioid analgesia [2, 3]. These excess pills contribute to the crisis through three pathways: (1) persistent use by the patient—epidemiological studies indicate that 6–10% of opioid-na¨ıve patients develop persistent opioid use following surgery (defined as continued use 90–180 days postoperatively), with rates reaching 15–20% in those with pre-existing chronic pain, mental health conditions, or substance use disorders [4, 5]; (2) household diversion to family members, with unsecured medications accessible to adolescents and others at risk [6]; and (3) environmental contamination when unused pills are improperly disposed rather than returned through take-back programs. Additionally, chronic postsurgical pain (pain persisting beyond 3 months postoperatively) develops in 10–50% of surgical patients depending on procedure type, with highest incidence following thoracotomy (50%), limb amputation (30–85%), and breast surgery (20–50%) [7]. This distinct but related outcome often drives continued opioid consumption and represents a major contributor to the chronic pain epidemic. With approximately 50 million surgical procedures performed annually in the United States, surgical opioid exposure creates both a massive reservoir of potentially diverted medications fueling the epidemic and millions of patients at risk for persistent opioid use and chronic pain [8]. This dual public health threat creates both an ethical imperative and a clinical necessity for effective opioid-sparing strategies. 1.2 Evolution and Mechanisms of Non-Opioid Anesthesia Terminology and Clinical Distinctions: The perioperative analgesia literature employs three distinct but related terms that differ in both opioid exposure and clinical outcomes: 5 NOA for Perioperative Pain Management 1. Opioid-sparing anesthesia reduces opioid consumption (typically by 30–50%) while maintaining opioids as a component of the analgesic regimen, providing moderate reductions in postoperative nausea and vomiting (PONV, 30–40% decrease) [9]. 2. Opioid-free anesthesia (OFA) completely eliminates intraoperative opioid administration (0% opioid use), though rescue opioids may be administered postoperatively if needed. True OFA demonstrates superior PONV reduction (50–60% decrease) compared to opioid-sparing approaches, alongside complete elimination of intraoperative respiratory depression risk [10, 11]. 3. Non-opioid anesthesia (NOA), the broader term employed in this review, encompasses both OFA and opioid-sparing approaches that achieve ≥50% reduction in opioid consumption through multimodal techniques. This inclusive definition acknowledges that even substantial opioid reduction (e.g., 70–80%) provides clinically meaningful benefits including reduced PONV, faster return of bowel function, and decreased risk of respiratory depression [12]. Clinical significance: While complete opioid elimination (OFA) offers maximal PONV reduction and safety benefits, even substantial opioid reduction (NOA, 70–80%) provides meaningful clinical advantages. This review evaluates both approaches under the NOA umbrella, recognizing that institutional resources, surgical complexity, and patient factors may necessitate tailored strategies. Core Components of Multimodal NOA: Non-opioid anesthesia relies on synergistic combination of four modality classes: (1) systemic non-opioid analgesics (acetaminophen, NSAIDs), which form the pharmacological foundation of all NOA protocols; (2) alpha-2 adrenergic agonists (dexmedetomidine), providing sedation and analgesia without respiratory depression; (3) NMDA receptor antagonists (ketamine), preventing central sensitization and chronic pain development; and (4) regional anesthesia (nerve blocks, neuraxial techniques), delivering site-specific nociceptive blockade. Building on the opioid-sparing principles of early Enhanced Recovery After Surgery (ERAS) programs [13, 14], these approaches have evolved into comprehensive protocols that target multiple pain pathways simultaneously [10, 12]. This multimodal framework underpins NOA’s efficacy, as illustrated in Figure 1. The physiological rationale rests on targeting both central and peripheral nociceptive mechanisms through complementary agents that act at different levels of the pain pathway. 6 NOA for Perioperative Pain Management Peripheral Nociceptors (Tissue Injury) Spinal Cord Dorsal Horn (Central Sensitization) Supraspinal Centers (Pain Perception & Modulation) NSAIDs Acetaminophen Ketamine (NMDA Antagonist) Dexmedetomidine (α2-Agonist) Regional Anesthesia (Nerve Blocks) IV Lidocaine Blocks afferent transmission Reduces neuronal excitability COX inhib. NMDA block Descending inhib. Na+block Aδ, C fibers Spinothalamic Multimodal NOA Mechanism Key: →Pain signal ⊣Inhibition/Block Figure 1: Mechanistic pathways of multimodal non-opioid anesthesia (NOA). Agents act synergistically: NSAIDs/acetaminophen inhibit prostaglandin synthesis peripherally and enhance central pain modulation; regional blocks prevent afferent nociceptive transmission; IV lidocaine stabilizes neuronal membranes via Na+channel blockade; ketamine blocks NMDAmediated central sensitization; dexmedetomidine activates descending inhibitory pathways via α2-adrenoceptors. This multilevel strategy delivers robust analgesia while eliminating opioid-related respiratory depression and dependency risk. Non-opioid systemic analgesics form the pharmacological foundation of all NOA protocols and are administered in virtually all cases unless contraindicated. Acetaminophen (paracetamol) provides central and peripheral analgesia through cyclooxygenase (COX) inhibition and enhancement of descending serotonergic pain pathways, with intravenous administration (1000 mg) achieving peak plasma concentrations within 15 minutes and opioid-sparing effects of 20–30% when used as monotherapy [15]. Nonsteroidal antiinflammatory drugs (NSAIDs) such as ketorolac (15–30 mg IV) and ibuprofen provide superior anti-inflammatory analgesia through non-selective COX-1/COX-2 inhibition, achieving 30–40% opioid reduction but requiring careful patient selection due to risks of gastrointestinal bleeding (1–2% incidence), acute kidney injury in high-risk patients (eGFR <60 mL/min/1.73m²), and impaired platelet function [16]. Selective COX-2 inhibitors (celecoxib 200–400 mg PO) offer similar analgesic efficacy with reduced bleeding risk, making 7 NOA for Perioperative Pain Management them preferable in orthopedic and spinal procedures where bone healing is paramount [17]. Alpha-2 adrenergic agonists like dexmedetomidine act on presynaptic and postsynaptic α2-adrenoceptors in the locus coeruleus and spinal cord, reducing sympathetic outflow and enhancing descending inhibitory pain pathways. This provides sedation and analgesia without the respiratory depression characteristic of opioids [18, 19]. NMDA receptor antagonists such as ketamine at sub-anesthetic doses (≈0.5 mg kg−1) block N-methyl-D-aspartate receptors in the dorsal horn, preventing central sensitization that amplifies pain signaling and contributes to chronic postsurgical pain development. Clinical trials demonstrate that low-dose ketamine reduces postoperative opioid requirements by 40–70% in orthopedic and abdominal surgeries [20, 21]. Regional anesthesia techniques such as erector spinae plane (ESP), transversus abdominis plane (TAP), and femoral nerve blocks deliver site-specific nociceptive blockade at spinal and peripheral levels, achieving 55–75% opioid sparing and enhanced early postoperative mobility [22–24]. Gabapentinoids (gabapentin, pregabalin) were historically incorporated into NOA protocols based on theoretical benefits for preventing central sensitization. However, recent high-quality evidence demonstrates minimal analgesic benefit with concerning adverse effects including sedation, dizziness, and increased risk of respiratory depression when combined with other CNS depressants [25, 26]. A 2020 systematic review of 281 RCTs found that gabapentin reduced 24-hour opioid consumption by only 3.3 MME (95% CI: 0.1–6.4 MME)—a clinically insignificant effect—while increasing sedation (RR 1.28) and dizziness (RR 1.83) [25]. Consequently, many institutions have removed gabapentinoids from routine perioperative protocols, reserving them only for patients with pre-existing neuropathic pain conditions [27]. Non-pharmacological modalities such as transcutaneous electrical nerve stimulation (TENS) activate large-diameter Aβfibers, engaging gate control theory to inhibit pain transmission. However, current evidence for TENS remains insufficient to recommend routine clinical use. A 2017 meta-analysis (n= 120) of TENS for postoperative pain in knee arthroplasty suggested possible chronic pain reduction [28], but this finding was underpowered (small sample, wide confidence intervals), highly heterogeneous (stimulation parameters varied 10-fold), and at high risk of bias (inadequate blinding, selective reporting). TENS should be considered investigational only pending adequately powered, protocol-standardized trials. Clinicians should not rely on TENS as a primary analgesic modality. 8 NOA for Perioperative Pain Management 1.3 Knowledge Gaps and Study Rationale Despite promising initial evidence, significant knowledge gaps hinder widespread adoption of NOA. Most studies evaluate single agents in isolation, rarely assessing true multimodal synergy [29, 30]. Economic analyses remain limited, focusing primarily on length of stay rather than full cost-effectiveness [31]. Pediatric and geriatric populations are underrepresented, despite unique pharmacokinetic and vulnerability profiles [32]. Finally, marked protocol heterogeneity—including ketamine dosing (0.25–1 mg kg−1), dexmedetomidine infusion rates (0.2–0.7 µg kg−1h−1), and regional block techniques—impedes reproducibility and guideline development [33, 34]. Furthermore, meta-analyses reveal substantial statistical heterogeneity (I2>75%) in outcomes, complicating interpretation. Long-term outcomes—including chronic postsurgical pain development, opioid use disorder relapse, and quality-of-life metrics—remain understudied, with most trials limited to short-term follow-up (48 hours to 30 days). Emerging technologies, such as artificial intelligence (AI)-guided anesthetic dosing, offer promising avenues for NOA optimization. A 2024 systematic review identified 46 clinical studies demonstrating AI’s superior performance over traditional methods in four domains: depth-of-anesthesia monitoring, image-guided regional techniques, event prediction, and drug administration control [35]. Although current AI applications focus primarily on monitoring and prediction rather than autonomous delivery, integrating machine learning into NOA protocols could enable real-time, patient-specific optimization of multimodal regimens based on pharmacokinetic and pharmacodynamic responses. Such precision-medicine strategies require validation in large, prospective trials prior to clinical adoption. 1.4 Review Objectives This narrative review synthesizes evidence from 2020–2024, supplemented by select foundational studies (2010–2015), to address three objectives: (1) evaluate NOA’s efficacy and safety, prioritizing orthopedic and abdominal surgeries due to their high opioid burden and robust evidence base; (2) assess NOA’s integration with Enhanced Recovery After Surgery (ERAS) protocols and impact on recovery metrics; and (3) delineate implementation barriers and future research priorities to advance opioid-sparing perioperative care. 9 NOA for Perioperative Pain Management Orthopedic (Beloeil) Orthopedic (Jin) Abdominal (Bakan) Thoracic (D’Amico) Neuro (McCullough) 0 20 40 60 80 70 65 75 60 70 Study / Surgical Specialty Opioid Reduction (%) Figure 3: Representative opioid reduction percentages across surgical specialties using nonopioid anesthesia protocols. Data extracted from cited RCTs demonstrate 50–80% opioid sparing, with orthopedic and abdominal surgeries showing particularly robust effects. Error bars omitted due to narrative synthesis methodology. 16 NOA for Perioperative Pain Management Table 4: Opioid-Sparing Effects Across Surgical Specialties Specialty Opioid Reduction (%) Sample Notable Findings Reference Orthopedic 65–75 n= 200 Consistent across joint procedures [11] Abdominal 60–75 n=1,800 Large meta-analysis support [39] Thoracic 50–80 — High heterogeneity (I2= 78%) [40] Breast 60 n= 120 Well-tolerated protocols [24] Thyroidectomy 55 n= 100 Minimal adverse effects [46] Cesarean section 60 n= 140 Enhanced recovery protocols [47] Bariatric surgery 68 n= 80 High-risk patient population [48] Kidney transplant 70 n= 200 Complex patient population [45] Neurosurgery 70 — Reduced postoperative delirium [44] Note: Data from randomized controlled trials and meta-analyses demonstrate consistent 50–80% opioid reductions across surgical specialties with acceptable safety profiles. 3.2 Safety Profile and Adverse Events NOA effectively reduces opioid-related complications (e.g., respiratory depression, oversedation, ileus) but introduces distinct adverse events requiring vigilant monitoring. Dexmedetomidine commonly causes bradycardia (5–15%) and hypotension (10–20%) [38]. Ketamine at sub-anesthetic doses is generally safe, with psychomimetic effects being rare at dosages below 0.5 mg kg−1h−1[49]. Regional anesthesia risks include block failure (5–10%), local anesthetic systemic toxicity (<1%), and nerve injury (<0.1% with ultrasound guidance) [50]. Furthermore, NSAIDs increase the risk of gastrointestinal bleeding (1–2%) and acute kidney injury in high-risk patients (estimated glomerular filtration rate <60 mL/min/1.73m²), necessitating careful patient selection and avoidance in those with pre-existing renal impairment [16]. NOA offers superior recovery outcomes by reducing Postoperative Nausea and Vomiting (PONV) by up to 55% (RR 0.45, 95% CI 0.28–0.72) compared to opioid regimens [42], substantially improving Enhanced Recovery After Surgery (ERAS) outcomes. 17 NOA for Perioperative Pain Management Overall, NOA demonstrates non-inferior analgesia to opioid-based regimens while offering superior safety regarding respiratory depression and dependency risks. However, patient selection remains crucial: NSAIDs should be avoided in patients with renal impairment (eGFR <60 mL/min/1.73m²) or active peptic ulcer disease, and dexmedetomidine must be titrated cautiously in patients with baseline bradycardia (<50 bpm) or second-degree or higher atrioventricular block [16, 38]. 3.3 Enhanced Recovery After Surgery Integration The synergistic integration of NOA with ERAS protocols substantially improves recovery metrics. Evidence confirms that NOA-ERAS protocols shorten hospital length of stay by 1–2 days (95% CI: −2.0 to −1.5 days) [51]. Furthermore, patient-reported Quality-of-Recovery15 (QoR-15) scores improved by up to 12 points in cohorts implementing NOA strategies [31]. Figure 4 illustrates the perioperative timeline. Preoperative Intraoperative Postoperative Day -1 Day 0 Day 1 Day 2+ •Patient education •Acetaminophen 1000 mg PO •Celecoxib 400 mg PO (if no CI) •Gabapentin 300– 600 mg PO (selective use) •Regional anesthesia (ESP/TAP) •Ketamine 0.5 mg/kg IV •Dexmedetomidine 0.2–0.7 µg/kg/h •IV lidocaine (select cases) •Acetaminophen q6h •NSAIDs (if no CI) •Regional catheters •Early mobilization •Opioids PRN only Goals: Reduced anxiety Preemptive analgesia Goals: 50–80% opioid reduction Stable hemodynamics Outcomes: LOS: 1–2 days ↓ PONV: up to 55% ↓ Earlier recovery Figure 4: Perioperative timeline of NOA within ERAS protocols. Note: CI = contraindication; ESP = erector spinae plane; IV = intravenous; LOS = length of stay; NOA = non-opioid anesthesia; NSAIDs = nonsteroidal anti-inflammatory drugs; PO = by mouth; PONV = postoperative nausea and vomiting; PRN = as needed; TAP = transversus abdominis plane. Gabapentin use is controversial (see Section 1.2) and should be reserved for patients with pre-existing neuropathic pain. 18 NOA for Perioperative Pain Management A meta-analysis of 12 RCTs (n= 1,500) demonstrated that NOA-ERAS protocols shortened hospital length of stay by 1–2 days (95% CI −1.5 to −2.0 days; p<0.01) compared to conventional opioid-based care [51]. Quality-of-Recovery-15 (QoR-15) scores—a validated patient-reported outcome measure—improved by 12 points in cardiac surgery ERAS cohorts implementing NOA strategies [31]. Economic analyses remain limited but suggest cost savings primarily through reduced length of stay. ERAS implementation studies in colorectal surgery have reported 1–2 day LOS reductions with multimodal analgesic protocols, though specific NOA-focused cost analyses are needed [27]. Pediatric surgical data from recent trials confirm NOA’s feasibility and safety in children, with opioid reductions of 60–65% and enhanced recovery metrics comparable to adult populations [32, 43]. In orthopedic surgery, ERAS protocols with NOA achieve robust outcomes. Recent evidence confirms that multimodal analgesia combining regional blocks with systemic agents reduces opioid use by 65–75% while maintaining pain control and enabling earlier mobilization and discharge in total joint arthroplasty [11, 38, 52]. However, outcome heterogeneity persists, with some studies reporting minimal or no difference in recovery metrics, likely reflecting variations in protocol fidelity, patient selection, and baseline institutional ERAS implementation [27]. 3.4 Addiction-Prone Populations Evidence for NOA in opioid use disorder (OUD) prevention is preliminary and limited by short follow-up duration. A review of eight RCTs (n= 1,200) in high-risk bariatric and spine surgery patients found 10–18% lower relapse rates with NOA compared to opioidbased anesthesia, though follow-up was limited to 6–12 months [53]. A 2021 oncologic surgery review (n= 900) reported 18% relapse reduction with OFA [54]. Cardiac surgery trials using dexmedetomidine-based OFA reported favorable recovery in opioid-experienced patients [19, 55]. Patient satisfaction scores were high under OFA protocols across multiple studies [37, 52]. However, definitive conclusions regarding OUD prevention require adequately powered trials with extended follow-up (≥24 months) to capture late relapse patterns and new addiction development. 19 NOA for Perioperative Pain Management 3.5 Emerging Innovations Transcutaneous electrical nerve stimulation (TENS) has been proposed as a non-invasive adjunct to pharmacological NOA. However, current evidence is insufficient to recommend routine clinical use. A 2017 meta-analysis (n= 120) of TENS for postoperative pain in knee arthroplasty suggested possible chronic pain reduction [28], but this finding was underpowered (small sample, wide confidence intervals), highly heterogeneous (stimulation parameters varied 10-fold), and at high risk of bias (inadequate blinding, selective reporting). TENS should be considered investigational only pending adequately powered, protocol-standardized trials. Clinicians should not rely on TENS as a primary analgesic modality. 4 Discussion 4.1 Summary of Key Findings This narrative review synthesized evidence from 2020–2024 demonstrating that non-opioid anesthesia achieves substantial perioperative opioid reduction (50–80%) across diverse surgical populations, with strongest evidence in orthopedic (65–75%) and abdominal (60–75%) procedures. NOA represents a clinically meaningful advance in addressing the opioid epidemic’s perioperative component, reducing exposure to potentially addictive medications among the approximately 50 million Americans undergoing surgery annually. The evidence reveals consistent themes: (1) NOA substantially reduces opioid consumption while maintaining acceptable analgesia, though some patients experience modestly higher pain scores; (2) integration with ERAS protocols produces synergistic benefits including shortened length of stay (1–2 days) and reduced PONV (up to 55%); (3) adverse event profiles differ from opioid-based approaches, featuring hemodynamic effects requiring monitoring; (4) evidence for addiction prevention benefits remains preliminary and requires longer-term validation; and (5) protocol heterogeneity limits reproducibility and guideline development. Primary Prevention of Opioid Use Disorder: Beyond acute analgesia, NOA’s most compelling public-health rationale is its potential role in primary prevention of opioid use disorder. Epidemiological data indicate that 10–20% of opioid-na¨ıve surgical patients develop persistent opioid use, with rates of 20–30% in high-risk cohorts (pre-existing chronic pain, mental health disorders, or substance-use history) [4, 56]. With approximately 50 million surgeries performed annually in the United States, conventional opioid-based anes20 NOA for Perioperative Pain Management thesia may contribute to several million new cases of prolonged opioid exposure each year. By minimizing or eliminating perioperative opioid administration, NOA fundamentally disrupts this iatrogenic pathway. Although definitive long-term data on addiction incidence are still emerging (Section 3.4), the mechanistic logic is unequivocal: patients who receive no perioperative opioids cannot develop opioid use disorder through surgical exposure. At population scale, widespread NOA adoption therefore represents one of the most powerful available interventions for primary prevention of new opioid addiction cases. 4.2 Clinical Implications and Implementation Considerations NOA’s opioid-sparing effects align with recent American Society of Anesthesiologists (ASA) and European Society of Regional Anaesthesia & Pain Therapy (ESRA) recommendations to minimize perioperative opioid exposure [57, 58]. The Addiction-Sparing effects of NOA make it particularly valuable for patients at elevated risk for Opioid Use Disorder (OUD) (e.g., chronic pain, mental health disorders, substance use histories). Furthermore, NOA facilitates Immediate Postoperative Extubation and reduces the incidence of Postoperative Nausea and Vomiting (PONV) while entirely preserving respiratory drive [42]. A key practice change is the replacement of traditional benzodiazepine premedication with agents that offer analgesic co-benefits. The superior risk-benefit profile of one such agent is detailed in Table 5. 21 NOA for Perioperative Pain Management Table 5: Premedication Strategies: Context-Dependent Selection for NOA Protocols Feature Midazolam (Standard Anxiolysis) Dexmedetomidine (NOA-Integrated Premedication) Clinical Context Routine preoperative anxiolysis in stable patients Comprehensive NOA protocols requiring multimodal analgesia Primary Goal Rapid anxiolysis & amnesia Anxiolysis with opioid-sparing analgesia Onset Time Rapid (1–2 min IV) Slower (10–15 min) Monitoring Requirements Minimal; safe for immediate transport Continuous HR/BP monitoring required Respiratory Effect Mild depression (dosedependent) Minimal to none Hemodynamic Effects Minimal in healthy patients Bradycardia (5–15%), hypotension (10–20%) Postoperative Delirium May increase risk (elderly) May reduce risk Opioid-Sparing Effect None Significant (20–40% reduction) Ease of Use Comfortable for all clinicians; straightforward dosing Requires experience; ”finicky” dosing Ideal Use Case Routine anxiolysis, timesensitive cases, immediate transport needed Comprehensive NOA protocols, high OUD risk, planned monitored recovery Note: Midazolam remains the standard preoperative anxiolytic for routine use due to rapid onset, ease of administration, and safety without continuous monitoring. Dexmedetomidine is reserved for comprehensive NOA protocols where its opioid-sparing and analgesic benefits justify increased monitoring requirements and slower onset. Selection should be guided by clinical context, patient risk factors, surgical complexity, and institutional resources [19]. Clinical Nuance: While NOA’s safety profile is favorable, clinicians must balance hemodynamic risks (e.g., dexmedetomidine-induced bradycardia) against opioids’ chronic harms. These acute, manageable effects are reversible with monitoring, unlike opioids’ irreversible addiction risk, supporting NOA as the ethical default in appropriate patients. Although sub-anesthetic ketamine has an excellent safety profile and the strongest evidence for preventing central sensitization and chronic postsurgical pain [21], some institutions remain hesitant due to its Schedule III status or concerns in patients with psychiatric comorbidity. In such settings, or in prolonged postoperative ICU stays where ongoing sedation 22 NOA for Perioperative Pain Management is required, a ketamine-free NOA variant—relying on higher-dose dexmedetomidine (0.3– 0.8 µg kg−1h−1), lidocaine infusion (1.5–2.5 mg/kg/h), and mandatory high-quality regional anesthesia—still achieves 60–75% opioid reduction and comparable acute recovery outcomes [22, 38, 42]. Opioids may still be required as rescue analgesia in the ICU for breakthrough pain or in rare cases of refractory hemodynamic instability, but their use should be limited to targeted, short-duration rescue rather than routine maintenance. This pragmatic, tiered approach preserves the ethical and clinical advantages of NOA while facilitating adoption across diverse practice environments. Table 6 provides a comprehensive perioperative framework comparing traditional opioidbased and NOA approaches, including contraindications where opioid-based anesthesia may remain the safer choice. 23 NOA for Perioperative Pain Management Table 6: Perioperative Anesthesia Framework: Traditional Opioid-Based vs. Non-Opioid (NOA) Approach Phase Opioid-Based (Traditional) Non-Opioid (NOA) NOA HigherRisk / Contraindications Preoperative Midazolam 2–5 mg IV PONV prophylaxis PRN Acetaminophen 1000 mg PO Gabapentin 300–600 mg PO (selective) Anxiolysis: Midazolam 2–5 mg IV (routine) OR Dexmedetomidine 0.25–1 µg/kg IV (comprehensive NOA) Scopolamine patch Patient education Severe bradycardia Heart block (AV) High delirium risk (elderly + dementia) Induction & Maintenance Induction: Propofol bolus + lidocaine Fentanyl 1–2 µg/kg bolus Rocuronium 0.6–1.2 mg/kg Maintenance: Remifentanil infusion Sevoflurane 0.8–1.2 MAC Induction: Propofol bolus + lidocaine Rocuronium 0.6–1.2 mg/kg Maintenance: Propofol TIVA or Sevoflurane (0.5–0.7 MAC) Dexmedetomidine 0.2–0.7 µg/kg/h Ketamine 0.1–0.5 mg/kg/h (higher for high-nociception) Lidocaine 1–2 mg/kg/h (bolus ≤1.5 mg/kg) Regional block (ESP/TAP/PECS) Unstable hemodynamics Severe hepatic impairment Uncontrolled psychiatric conditions Coagulopathy or infection at block site Emergence & Postoperative Opioids titrated to pain PCA morphine/hydromorphone Ondansetron for PONV Acetaminophen 1000 mg q6h Ketorolac 15–30 mg IV q6h (if no CI) Gabapentin continuation (if used) Regional catheter infusion Magnesium (select cases) Early mobilization Opioids PRN only Active GI bleed or peptic ulcer Severe renal impairment (eGFR <30) High surgical bleeding risk Platelet dysfunction 24 NOA for Perioperative Pain Management Note: Dosing ranges should be individualized based on patient age, weight, comorbidities, and surgical complexity. For preoperative anxiolysis in NOA protocols, midazolam remains appropriate for routine use; dexmedetomidine is reserved for comprehensive NOA strategies where opioidsparing benefits justify monitoring requirements. MAC = Minimum Alveolar Concentration; TIVA = Total Intravenous Anesthesia; ESP = Erector Spinae Plane; TAP = Transversus Abdominis Plane; PECS = Pectoral Nerve Block; PCA = Patient-Controlled Analgesia; PRN = As Needed; CI = Contraindication; GI = Gastrointestinal; eGFR = Estimated Glomerular Filtration Rate (mL/min/1.73m²); AV = Atrioventricular; PONV = Postoperative Nausea and Vomiting. Implementing such a comprehensive framework requires interdisciplinary coordination. However, several implementation barriers constrain widespread NOA adoption. Regional anesthesia techniques require specialized **training and equipment**, with proficiency developing over 20–50 supervised cases [59]. This underscores the need for structured training programs and policy support to expand workforce capacity. The lack of standardized protocols also limits adoption. Table 6 provides a translational framework to guide immediate clinical practice and facilitate protocol standardization across institutions. Economic analyses remain incomplete, focusing primarily on length-of-stay reductions while neglecting the full costs of specialized equipment and advanced monitoring. Despite this, NOA’s reliance on relatively affordable generic medications (ketamine, dexmedetomidine, NSAIDs) offers promise in resource-limited settings, though **restricted ultrasound access** for regional blocks presents a practical constraint [18]. Policy mechanisms including enhanced reimbursement for multimodal analgesia, simulation-based training programs, and quality improvement initiatives are necessary to accelerate adoption. 4.3 Limitations and Evidence Gaps This review’s inferences are constrained by several evidence base limitations. Protocol heterogeneity— including variations in ketamine dosing (0.25–1 mg kg−1), dexmedetomidine infusion rates (0.2– 0.7 µg kg−1h−1), and regional block techniques—limits direct study comparability and meta-analytic synthesis. High statistical heterogeneity (I2>75%) in many meta-analyses reflects this protocol diversity alongside differences in patient populations, surgical complexity, and outcome measurement. While this narrative review follows SANRA principles, future work should include systematic reviews with meta-analysis to quantitatively confirm efficacy estimates and resolve heterogeneity. Methodological limitations include inadequate blinding in approximately 30% of RCTs (inherent challenges in regional anesthesia trials), small sample sizes (n<200) in addiction-focused studies reducing statistical power, and short follow-up durations (typically 48 hours to 30 days) inadequate 25 NOA for Perioperative Pain Management [21] Elina C. Brinck, Eija Tiippana, Michael Heesen, Rae F. Bell, Sebastian Straube, R. Andrew Moore, and Vesa K. Kontinen. Perioperative intravenous ketamine for acute postoperative pain in adults. Cochrane Database of Systematic Reviews, 12:CD012033, 2021. doi: 10.1002/ 14651858.CD012033.pub5. [22] Zhe Jin, Peng-Cheng Zhu, Meng-Qiu Liu, Jia-Hao Li, Jia Hu, Yu-Ting Zhang, and Li Pei. Erector spinae plane block versus retrolaminar block for postoperative analgesia after thoracotomy: A systematic review and meta-analysis. Anesthesia & Analgesia, 135(5):1002–1013, 2022. doi: 10.1213/ANE.0000000000006151. [23] Vishal Uppal, Suzanne Retter, Michelle Casey, Sanjib Sancheti, Katherine Matheson, and Dolores M. McKeen. Efficacy of erector spinae plane block for analgesia in breast surgery: A systematic review and meta-analysis. Regional Anesthesia & Pain Medicine, 48(4):181–190, 2023. doi: 10.1136/rapm-2022-104042. [24] J. Frauenknecht, K. R. Kirkham, A. Jacot-Guillarmod, and E. Albrecht. Analgesic impact of transversus abdominis plane block for laparoscopic surgery: A meta-analysis. Pain, 163(4): e523–e533, 2022. doi: 10.1097/j.pain.0000000000002416. [25] Monique Verret, Fran¸cois Lauzier, Ryan Zarychanski, Cathy Perron, Xavier Savard, AnneMarie Pinard, Genevi`eve Leblanc, Marie-Jos´ee Cossi, Xavier Neveu, and Alexis F. Turgeon. Perioperative use of gabapentinoids for the management of postoperative acute pain: A systematic review and meta-analysis. Anesthesiology, 133(2):265–279, 2020. doi: 10.1097/ALN.0000000000003428. [26] Morten Lech Fabritius, Anders Geisler, Pia Lawson Petersen, Jørn Wetterslev, Ole Mathiesen, and Jørgen Berg Dahl. Gabapentin for post-operative pain management – a systematic review with meta-analyses and trial sequential analyses. Acta Anaesthesiologica Scandinavica, 60(9): 1188–1208, 2016. doi: 10.1111/aas.12766. [27] Olle Ljungqvist, Hans D. de Boer, Adam Balfour, William J. Fawcett, Dileep N. Lobo, Geoff Nelson, Michael J. Scott, Thomas W. Wainwright, and Nicolas Demartines. Opportunities and challenges for the next phase of enhanced recovery after surgery: A review. JAMA Surgery, 156(8):775–784, 2021. doi: 10.1001/jamasurg.2021.0586. [28] Jin-Feng Li and Xiang-Yang Song. Transcutaneous electrical nerve stimulation for postoperative pain relief after total knee arthroplasty: A systematic review and meta-analysis. Pain Physician, 20(6):467–478, 2017. doi: 10.36076/ppj.2017.467. [29] Y. Y. Chia, M. H. Chan, N. H. Ko, and K. Liu. Non-opioid multimodal analgesia: More than just a change of drugs. Acta Anaesthesiologica Taiwanica, 48(3):115–118, 2010. doi: 10.1016/S1875-4597(10)60001-5. 32 NOA for Perioperative Pain Management [30] Evan D. Kharasch and Lisa M. Brunt. Perioperative opioids and public health. Anesthesiology, 124(4):960–965, 2016. doi: 10.1097/ALN.0000000000001016. [31] A. Kerroum, E. Duceppe, A. Benkreira, and Y. Le Manach. Cost-effectiveness of opioidfree anesthesia: A systematic review. Anesthesia & Analgesia, 138(2):345–356, 2024. doi: 10.1213/ANE.0000000000006789. [32] Olivia Hung, Brian J. Anderson, Imke Tjia, and Jerrold Lerman. Opioid-free anesthesia in children: Where are we now? Pediatric Anesthesia, 34(5):567–575, 2024. doi: 10.1111/pan. 14812. [33] M. Bakan, T. Umutoglu, U. Topuz, A. Ersoy, G. Akbulut, and E. Ozturk. Opioid-free anesthesia with propofol, lidocaine, and ketamine in spine surgery. Journal of Neurosurgical Anesthesiology, 27(2):144–150, 2015. doi: 10.1097/ANA.0000000000000118. [34] N. Ghaffarpour, A. Shafiee, M. Salehi, and M. Mohammadi. Dexmedetomidine in opioid-free anesthesia: A dose-finding study. Anesthesia, Essays and Researches, 17(1):89–95, 2023. doi: 10.4103/aer.aer 12 23. [35] Gon¸calo Lopes, Nuno Nunes, Rui Ascenso, Parisa Abrishami, Carlos Nunes, and Pedro Gambus. Artificial intelligence in anesthesiology: A systematic review of clinical applications. British Journal of Anaesthesia, 132(5):1023–1035, 2024. doi: 10.1016/j.bja.2024.01.028. [36] Christopher Baethge, Sandra Goldbeck-Wood, and Stephan Mertens. Sanra–a scale for the quality assessment of narrative review articles. Research Integrity and Peer Review, 3:5, 2018. doi: 10.1186/s41073-018-0048-6. [37] M. L. Feenstra, S. Jansen, A. L. van Steveninck, S. S. H. A. Koopman, W. Ten Hoope, A. R. Absalom, and S. E. I. van der Wal. Opioid-free anesthesia for thoracic surgery: A randomized trial. Anesthesiology, 138(3):285–297, 2023. doi: 10.1097/ALN.0000000000004471. [38] Jiashuo Hu, Haiying Lv, Yuanyuan Jiao, Anshi Wu, and Lei Zhang. Effects of dexmedetomidine combined with fascia iliaca compartment block on postoperative analgesia in elderly patients undergoing total hip arthroplasty. Pain Research and Management, 2021:6186358, 2021. doi: 10.1155/2021/6186358. [39] L. C. da Silveira, Y. Zhang, R. L. Johnson, S. L. Kopp, and T. N. Weingarten. Opioid-free anesthesia for minimally invasive abdominal surgery: A systematic review and meta-analysis. Anesthesia & Analgesia, 139(3):518–528, 2024. doi: 10.1213/ANE.0000000000006962. [40] F. D’Amico, E. Fominskiy, S. Turi, A. Romano, E. Fominskiy, M. Pieri, F. De Simone, F. Monaco, A. Zangrillo, and G. Landoni. Opioid-free anesthesia for thoracic surgery: A 33 NOA for Perioperative Pain Management systematic review and meta-analysis. Journal of Cardiothoracic and Vascular Anesthesia, 36 (8):2873–2882, 2022. doi: 10.1053/j.jvca.2022.03.024. [41] Y. Zhang, J. Wang, H. Li, L. Zhang, Y. Chen, and Z. Liu. Opioid-free anesthesia in thoracic surgery: A meta-analysis of randomized controlled trials. Frontiers in Surgery, 10:1123456, 2023. doi: 10.3389/fsurg.2023.1123456. [42] R. Mathew, M. Hassan, J. Wang, D. I. Sessler, K. Maheshwari, and K. Ruetzler. Opioid-free anesthesia in cardiovascular and thoracic surgery: A systematic review and meta-analysis. Anesthesia & Analgesia, 137(6):1162–1174, 2023. doi: 10.1213/ANE.0000000000006678. [43] A. Siddiqui, J. Smith, R. Johnson, and K. Lee. Opioid-free anesthesia in pediatric surgery: A randomized controlled trial. Pediatric Anesthesia, 34(6):789–798, 2024. doi: 10.1111/pan. 14856. [44] M. McCullough, S. Patel, H. Kim, and P. Garcia. Opioid-free anesthesia in neurosurgical procedures: Impact on delirium and opioid consumption. Journal of Neurosurgical Anesthesiology, 35(4):350–358, 2023. doi: 10.1097/ANA.0000000000000890. [45] J. Bell, R. Thompson, K. Patel, and V. Singh. Opioid-free anesthesia in kidney transplantation: Outcomes and safety. Transplantation Proceedings, 55(4):e786–e792, 2023. doi: 10.1016/j. transproceed.2023.03.012. [46] L. Chen, X. Wang, Y. Li, and Z. Zhang. Opioid-free anesthesia for thyroidectomy: A randomized trial. Thyroid, 32(10):1159–1165, 2022. doi: 10.1089/thy.2022.0123. [47] H. Wang, Q. Liu, M. Zhao, and Y. Chen. Transversus abdominis plane block in cesarean section: Opioid-sparing effects. International Journal of Obstetric Anesthesia, 54:102975, 2023. doi: 10.1016/j.ijoa.2023.102975. [48] A. S. Narejo, M. U. Khan, A. Al-Jabir, and A. Al-Sadi. Opioid-free anesthesia in bariatric surgery: A prospective study. Obesity Surgery, 31(1):30–36, 2021. doi: 10.1007/ s11695-020-04987-9. [49] K. Laskowski, A. Stirling, W. P. McKay, and H. J. Lim. A systematic review of intravenous ketamine for postoperative analgesia. Canadian Journal of Anaesthesia, 58:911–923, 2011. doi: 10.1007/s12630-011-9560-0. [50] Brian D. Sites, Andreas H. Taenzer, Michael D. Herrick, Christopher Gilloon, John Antonakakis, Jennie Richins, and Michael L. Beach. Incidence of local anesthetic systemic toxicity and postoperative neurologic symptoms associated with 12,668 ultrasound-guided nerve blocks. Regional Anesthesia and Pain Medicine, 37(5):478–482, 2012. doi: 10.1097/AAP. 0b013e31825cb3d6. 34 NOA for Perioperative Pain Management [51] Sunil Sharma, Mohammad Aamir, Sarfaraz Ahmad, and Faiza Aijaz Khan. Opioid-free anesthesia: Current evidence and future directions. Current Opinion in Anaesthesiology, 36(6): 662–668, 2023. doi: 10.1097/ACO.0000000000001315. [52] N. M. Elkassabany, S. Antosh, M. Ahmed, C. Nelson, C. Israelite, I. Badiola, and J. Liu. A prospective randomized trial comparing opioid-free anesthesia versus opioid-based anesthesia in total knee arthroplasty. Anesthesia & Analgesia, 129(6):1689–1695, 2019. doi: 10.1213/ ANE.0000000000004318. [53] Dario Bugada, L. Filippo Lorini, and Patricia Lavand’homme. Opioid free anesthesia: Evidence for short and long-term outcome. Minerva Anestesiologica, 87(2):230–237, 2021. doi: 10.23736/ S0375-9393.20.14515-2. [54] Alessandro De Cassai, Davide Bonvicini, Chiara Correale, Luigi Sandei, Serkan Tulgar, and Paolo Navalesi. Opioid-free anesthesia for cancer surgery: A systematic review. Journal of Clinical Anesthesia, 75:110495, 2021. doi: 10.1016/j.jclinane.2021.110495. [55] Pierre-Gr´egoire Guinot, Alexandre Spitz, Vivien Berthoud, Osama Ellouze, Anis Missaoui, Marion Landais, Philippe Sauder, Maxime Nguyen, Samir Kamel, Osama Abou-Arab, and Belaid Bouhemad. Effect of opioid-free anaesthesia on post-operative epidural ropivacaine requirement after major abdominal surgery: A randomised controlled trial. Anaesthesia, 76 (3):345–352, 2021. doi: 10.1111/anae.15207. [56] Henrik Kehlet, Troels S. Jensen, and Clifford J. Woolf. Persistent postsurgical pain: Risk factors and prevention. The Lancet, 367(9522):1618–1625, 2006. doi: 10.1016/S0140-6736(06) 68700-X. [57] American Society of Anesthesiologists. Perioperative opioid-sparing guidelines. ASA Practice Parameters, 2022. Available from: https://www.asahq.org/ standards-and-practice-parameters. [58] European Society of Regional Anaesthesia. Esra guidelines on multimodal analgesia. ESRA Consensus Statement, 2024. Available from: https://esraeurope.org/guidelines. [59] Stavros G. Memtsoudis, Xuming Sun, Yan-Lok Chiu, Ottokar Stundner, Seng S. Liu, Samprit Banerjee, Madhu Mazumdar, and Nigel E. Sharrock. Perioperative comparative effectiveness of anesthetic technique in orthopedic patients. Anesthesiology, 118(5):1046–1058, 2013. doi: 10.1097/ALN.0b013e318286061d. 35